Compugen to Present New Clinical Data at SITC 2024
GSK, ITeos Lung Cancer Therapy Outperforms Jemperli in Mid-stage Trial
Compugen Shareholders Approve All Proposals
Compugen to Present at Single Cell Genomics 2024 Conference
This Is Why Compugen Ltd.'s (NASDAQ:CGEN) CEO Compensation Looks Appropriate
Compugen to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Can Compugen (CGEN) Run Higher on Rising Earnings Estimates?
Truist Financial Maintains Compugen(CGEN.US) With Buy Rating
Truist Financial analyst Asthika Goonewardene maintains $Compugen(CGEN.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 30.3% and a total average return of -6.6%
Party Time: Brokers Just Made Major Increases To Their Compugen Ltd. (NASDAQ:CGEN) Earnings Forecasts
Earnings Call Summary | Compugen(CGEN.US) Q2 2024 Earnings Conference
Compugen Ltd. (CGEN) Q2 2024 Earnings Call Transcript
Compugen: Strong Buy on Promising Trials, Strategic Alliances, and Solid Financials
News Flash: Analysts Just Made A Sizeable Upgrade To Their Compugen Ltd. (NASDAQ:CGEN) Forecasts
Compugen Ltd. (NASDAQ:CGEN): When Will It Breakeven?
Compugen 2Q Loss/Shr 2c >CGEN
Compugen GAAP EPS of -$0.02, Revenue of $6.7M
Compugen Q2 EPS $(0.02) Beats $(0.07) Estimate, Sales $6.70M
Press Release: Compugen Reports Second Quarter 2024 Results
Here Is the Next Potential Market Catalyst
Compugen Q2 2024 Earnings Preview